-
公开(公告)号：US20100210634A1
公开(公告)日：2010-08-19
申请号：US12772872
申请日：2010-05-03
IPC分类号： A61K31/541 , C07D401/12 , A61K31/496 , C07D413/14 , A61K31/4725 , C07D471/04 , C07D417/14 , A61K31/5377 , A61P9/04
CPC分类号： C07D413/12 , C07D213/75 , C07D295/13 , C07D295/145 , C07D401/12 , C07D413/14 , C07D417/14 , C07D471/04
摘要： Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
-
公开(公告)号：US20100029680A1
公开(公告)日：2010-02-04
申请号：US12483093
申请日：2009-06-11
申请人： Bradley P. Morgan , David J. Morgans, JR. , Alex Muci , Pu-Ping Lu , Erica A. Kraynack , Todd Tochimoto
发明人： Bradley P. Morgan , David J. Morgans, JR. , Alex Muci , Pu-Ping Lu , Erica A. Kraynack , Todd Tochimoto
IPC分类号： A61K31/496 , A61P9/00
CPC分类号： C07D213/75 , A61K31/496 , A61K31/4965 , A61K31/497 , A61K31/5377
摘要： Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
摘要翻译： 某些取代的脲衍生物选择性地调节心肌肉瘤，例如通过增强心肌肌球蛋白，并且可用于治疗包括充血性心力衰竭的收缩性心力衰竭。
-
公开(公告)号：US20090324511A1
公开(公告)日：2009-12-31
申请号：US12469603
申请日：2009-05-20
申请人： Bradley P. Morgan , Alex Muci , Erica Kraynack , Pu-Ping Lu , Todd Tochimoto , David J. Morgans, JR.
发明人： Bradley P. Morgan , Alex Muci , Erica Kraynack , Pu-Ping Lu , Todd Tochimoto , David J. Morgans, JR.
IPC分类号： A61K9/12 , A61K31/541 , A61K31/4439 , A61K31/41 , A61K31/40 , C07D417/12 , C07D285/10 , C07D207/12
CPC分类号： C07D417/12 , C07D513/04
摘要： Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
摘要翻译： 某些取代的脲衍生物选择性地调节心肌肉瘤，例如通过增强心肌肌球蛋白，并且可用于治疗包括充血性心力衰竭的收缩性心力衰竭。
-
![Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use](/abs-image/US/2009/10/06/US07598248B2/abs.jpg.150x150.jpg)
44.发明授权Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use 有权某些1H-咪唑并[4,5-b]吡嗪-2（3H） - 酮和1H-咪唑并[4,5-b]吡嗪-2-醇，其组合物及其使用方法公开(公告)号：US07598248B2
公开(公告)日：2009-10-06
申请号：US11888902
申请日：2007-08-01
申请人： Alex Muci , Jeffrey T. Finer , Pu-Ping Lu , Alan James Russell , Bradley P. Morgan , David J. Morgans, Jr.
发明人： Alex Muci , Jeffrey T. Finer , Pu-Ping Lu , Alan James Russell , Bradley P. Morgan , David J. Morgans, Jr.
IPC分类号： A61K31/497
CPC分类号： C07D487/04
摘要： Provided is at least one chemical entity chosen from compounds of Formula I and compounds of Formula II: and pharmaceutically acceptable salts thereof, compositions thereof, and methods for their use in modulating of one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, skeletal muscle, and skeletal sarcomere.
摘要翻译： 提供至少一种选自式I化合物和式II化合物的化学实体及其药学上可接受的盐，其组合物，及其用于调节骨髓肌球蛋白，骨骼肌动蛋白，骨骼原肌球蛋白，骨骼肌中的一种或多种的方法 肌钙蛋白C，骨骼肌钙蛋白I，骨骼肌钙蛋白T，骨骼肌和骨骼肌节。
-
![Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use](/abs-image/US/2011/06/07/US07956056B2/abs.jpg.150x150.jpg)
45.发明授权Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use 有权某些1H-咪唑并[4,5-B]吡嗪-2（3H） - 酮和1H-咪唑并[4,5-B]吡嗪-2-醇及其使用方法公开(公告)号：US07956056B2
公开(公告)日：2011-06-07
申请号：US12573730
申请日：2009-10-05
申请人： Alex Muci , Jeffrey T. Finer , Pu-Ping Lu , Alan James Russell , Bradley P. Morgan , David J. Morgans, Jr.
发明人： Alex Muci , Jeffrey T. Finer , Pu-Ping Lu , Alan James Russell , Bradley P. Morgan , David J. Morgans, Jr.
IPC分类号： A61K31/495
CPC分类号： C07D487/04
摘要： Provided is at least one chemical entity chosen from compounds of Formula I and Formula II: and pharmaceutically acceptable salts thereof, compositions thereof, and methods for their use in modulating one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, skeletal muscle, and skeletal sarcomere.
摘要翻译： 提供了至少一种选自式I和式II化合物的化学实体及其药学上可接受的盐，其组合物，及其用于调节骨骼肌球蛋白，骨骼肌动蛋白，骨骼原肌球蛋白，骨骼肌钙蛋白C中的一种或多种的方法， 骨骼肌肌钙蛋白I，骨骼肌钙蛋白T，骨骼肌和骨骼肌节。
-
公开(公告)号：US07825120B2
公开(公告)日：2010-11-02
申请号：US11639398
申请日：2006-12-13
申请人： Bradley P. Morgan , Alex Muci , Erica A. Kraynack , Todd Tochimoto , Pu-Ping Lu , David J. Morgans, Jr.
发明人： Bradley P. Morgan , Alex Muci , Erica A. Kraynack , Todd Tochimoto , Pu-Ping Lu , David J. Morgans, Jr.
IPC分类号： A61K31/497 , C07D241/04 , C07D295/00
CPC分类号： C07D401/12 , C07D213/75 , C07D239/42 , C07D261/14 , C07D403/12 , C07D413/12
摘要： Certain substituted ((piperazin-1-ylmethyl)benzyl)urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and may be useful in the treatment of systolic heart failure including congestive heart failure.
摘要翻译： 某些取代的（（哌嗪-1-基甲基）苄基）脲衍生物选择性地调节心肌肉瘤，例如通过增强心肌肌球蛋白，并且可用于治疗包括充血性心力衰竭的收缩性心力衰竭。
-
公开(公告)号：US20100093741A1
公开(公告)日：2010-04-15
申请号：US12573730
申请日：2009-10-05
申请人： Alex Muci , Jeffrey T. Finer , Pu-Ping Lu , Alan James Russell , Bradley P. Morgan , David J. Morgans, JR.
发明人： Alex Muci , Jeffrey T. Finer , Pu-Ping Lu , Alan James Russell , Bradley P. Morgan , David J. Morgans, JR.
IPC分类号： A61K31/4985 , C07D487/04 , A61P3/04 , A61P3/00 , A61P21/00
CPC分类号： C07D487/04
摘要： Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post-traumatic muscle weakness, neuromuscular disease, and other indications.
摘要翻译： 提供某些化学实体以及用于调节骨骼肌球蛋白，骨骼肌动蛋白，骨骼原肌球蛋白，骨骼肌钙蛋白C，骨骼肌钙蛋白I，骨骼肌钙蛋白T和骨骼肌（包括其片段和同种型）以及骨骼肌节的使用方法， 以及用于治疗肥胖，肌肉减少症，消瘦综合征，虚弱，恶病质，肌肉痉挛，手术后和创伤后肌肉无力，神经肌肉疾病等症状的治疗方法。
-
48.发明授权Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives 失效用杂环稠合嘧啶酮衍生物调节KSP驱动蛋白活性公开(公告)号：US07332498B2
公开(公告)日：2008-02-19
申请号：US11284806
申请日：2005-11-23
IPC分类号： A61K31/519 , A61K31/5025 , C07D471/04 , C07D487/04 , C07D498/04 , C07D211/78 , C07D211/82 , C07D211/70 , C07D211/90 , C07D211/72 , C07D211/84 , C07D213/84 , C07D213/72 , C07D213/78 , C07D213/46 , C07D213/56
CPC分类号： C07D471/04 , C07D475/02 , C07D487/04
摘要： A method of modulating KSP kinesin activity in vitro comprising contacting KSP kinesin with at least one chemical entity chosen from compounds represented by Formula I: and pharmaceutically acceptable salts thereof, where the variables are as defined further herein.
摘要翻译： 一种在体外调节KSP驱动蛋白活性的方法，包括使KSP驱动蛋白与至少一种选自式I表示的化合物的化学实体及其药学上可接受的盐接触，其中变量如本文进一步定义。
-
公开(公告)号：US08969346B2
公开(公告)日：2015-03-03
申请号：US13642207
申请日：2011-04-22
申请人： Luke W. Ashcraft , Gustave Bergnes , Scott Collibee , Chihyuan Chuang , Jeff Gardina , Bradley P. Morgan , Alex R. Muci , Xiangping Qian , Jeffrey M Warrington , Zhe Yang , Pu-Ping Lu , Antonio Romero
发明人： Luke W. Ashcraft , Gustave Bergnes , Scott Collibee , Chihyuan Chuang , Jeff Gardina , Bradley P. Morgan , Alex R. Muci , Xiangping Qian , Jeffrey M Warrington , Zhe Yang , Pu-Ping Lu , Antonio Romero
IPC分类号： A61K31/50 , C07D237/20 , C07D401/12 , C07D237/24 , C07D401/04 , C07D403/04 , C07D403/06 , C07D409/14 , C07D411/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D513/04 , C07D401/14 , C07D405/14
CPC分类号： A61K31/50 , A61K31/16 , A61K31/166 , C07D207/26 , C07D211/76 , C07D213/16 , C07D231/56 , C07D237/06 , C07D237/20 , C07D237/24 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/14 , C07D409/14 , C07D411/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D513/04 , Y02A50/465
摘要： Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
摘要翻译： 提供式I化合物或其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8，R 9，X和m如本文所定义。 还提供了包含式I化合物或其药学上可接受的盐的药学上可接受的组合物。 还提供了使用式I化合物或其药学上可接受的盐的方法。
-
公开(公告)号：US08962632B2
公开(公告)日：2015-02-24
申请号：US13642206
申请日：2011-04-22
申请人： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
发明人： Zhe Yang , Alex R. Muci , Jeffrey Warrington , Gustave Bergnes , Bradley P. Morgan , Chihyuan Chuang , Antonio Romero , Scott Collibee , Xiangping Qian , Pu-Ping Lu
IPC分类号： A61K31/505 , A61K31/4965 , C07D401/12 , C07D239/42 , C07D403/10 , A61K9/00 , C07D239/48 , C07D401/04 , C07D401/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04
CPC分类号： A61K9/0014 , A61K9/0019 , A61K9/0034 , A61K9/0043 , A61K9/0048 , A61K9/0053 , A61K9/006 , A61K9/007 , C07D239/42 , C07D239/48 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04
摘要： Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
77 条记录 (耗时 0.049 秒)
